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Dr Cary W. Akins (Boston, Mass). I congratulate Dr Gillinov
for his excellent presentation of this complex analysis of mitral
valve repair versus replacement when performed in combination
with aortic valve replacement. Unfortunately, I did not have the
manuscript long enough to fully evaluate the complex statistical
methods, even if I could have understood them, so I will try to look
at some of the basic issues concerning the study.
All surgical groups, including our own, who have reported the
advantages of mitral valve reconstruction versus replacement in
single valve disease have the a priori notion that the conclusion of
this manuscript must be correct. My innate prejudice favoring
mitral valve repair makes me believe the conclusion, but I am not
sure that the study actually proves the fact.
The study is retrospective and not randomized. The two patient
groups are different in significant ways. Although many factors
were assessed to try to statistically determine why surgeons chose
one operation over another, there are important areas of missing
information about factors that have been used to calculate propen-
sities and results.
Appendix Figure 1. Trends across time in management of patients with double valve disease. In these graphs, each
closed circle represents yearly proportion; a solid line is continuous probability by univariable logistic regression.
A, Proportion of patients in whom mitral valve was replaced; B, proportion of patients coming to operation with
rheumatic mitral valve disease versus degenerative mitral valve disease.
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For example, in the manuscript, for the 813 patients studied,
information on mitral valve pathophysiology, that is, stenosis or
regurgitation, was available for less than two thirds of the patients,
yet mitral valve stenosis is listed as a significant predictor of the
operation performed. Also, there are no data in the study on two
factors that are known to impact long-term survival in mitral valve
disease, namely the severity of the mitral valve disease as repre-
sented by levels of pulmonary hypertension or a history of stroke,
nor is the history of malignancy evaluated.
Many factors that lead surgeons who know their patients well
to choose one operation over another are often not well docu-
mented in a hospital chart, let alone quantifiable. It is my conten-
tion that surgeons can frequently judge which patients have limited
potential for long-term survival exclusive of their valvular disease
and will perform the operation that is most expedient. To then
attribute late all-cause death to the choice of operation seems
inappropriate. Even Dr. Blackstone’s extraordinary statistical pow-
ers can not accommodate for missing data or truly account for
surgeon bias.
There is another equally important feature of this nonprospec-
tive, nonrandomized trial that merits attention. The implication in
this comparative study is that mitral valve repair was an option for
all patients. I doubt that is true. Even in the hands of most
experienced surgeons, end-stage calcific mitral valve disease is not
amenable to reconstruction. The hypothesis of the study would be
easier to validate if the two patient groups studied both contained
only patients for whom repair was a viable option.
In terms of the operation performed, the authors do not discuss
the issue of chordal-sparing mitral valve replacement. Had this
technique been used with mitral valve replacement, do you believe
that there would have been better long-term results, as some
authors contend?
The authors also state that patients with rheumatic disease have
better survival rates than those with nonrheumatic disease and
suggest that it is due to better preserved ventricular function, but
they did not relate this to the presence of concomitant coronary
artery disease. Could concomitant coronary artery disease be the
reason for your findings?
I again congratulate Dr. Gillinov and his colleagues at the
Cleveland Clinic on this provocative study, and, although I want to
believe the inference, I am not sure that it has been proven.
Dr Gillinov. I will try to address all those points one by one,
although this may take a while. You are absolutely correct, this is
a retrospective clinical study. It is not a randomized prospective
study. Such a study would be virtually impossible to perform, and,
therefore, we have to analyze the data that are available, and we
have done our best to do that. You do note that we have not
reported the pathophysiology of mitral valve disease in about one
third of the patients. The patients for whom we have specified the
pathophysiology are those who had either preoperative or intraop-
erative echocardiography. We are now going back to gather the
data that we can from catheterization reports, but we believe that
the data from echocardiography is more reliable because we can
more accurately judge the degree of mitral stenosis or regurgitation
in these patients. We will be supplementing the data with cathe-
terization reports.
We have not included the variable pulmonary hypertension. I
believe that is a good suggestion, and it would be valuable to go
back and gather that data and to determine the impact of preoper-
ative pulmonary hypertension on the outcome of these patients.
As far as comorbid conditions such as stroke and malignancy,
we do not make our decisions for the valvular procedure in a
vacuum. We try to choose the best procedure that applies to the
patient, and certainly a patient who has an extremely limited life
expectancy on the basis of a progressive cancer might get a
different operation from a 40-year-old individual. Again, though,
those sorts of variables, as you correctly state, are difficult to
capture in this sort of analysis.
We do not attribute all of the deaths in this study to the choice
of valve procedure. The people who died are dead. It really doesn’t
matter of what they died. However, we did find an important
relationship between the choice of valvular procedure and the
mortality rate, and we believe that this is, in fact, a true relation-
ship. We also agree, as everyone knows, mitral valve repair is not
an option for all patients. There are valves that can not be repaired.
We would temper our conclusions by saying mitral valve repair
should be considered in all patients. If it is a heavily calcified
rheumatic mitral valve with a completely fused subvalvular appa-
ratus, this valve probably can not be repaired and should be
replaced; and, when doing the replacement, on the basis of data
accumulated by Dr David and others, we currently do spare as
much of the subvalvular apparatus as possible. When looking for
this data in old operative reports, we were unable to find it in most
patients, and, therefore, we believed that it would be incorrect to
try to analyze an incomplete data set.
Finally, with regard to your question of could the better sur-
vival rate in patients with rheumatic disease be related to the
prevalence of coronary artery disease in these patients, the answer
is no. We did correct for the presence of coronary artery disease.
The patients with rheumatic disease simply lived longer.
Dr Tirone E. David (Toronto, Ontario, Canada). If you take a
look at the clinical outcomes of mitral valve surgery, aside from
things we know like age, New York functional class, and ventric-
ular function before disease, the pathologic process, unlike in the
aortic valve, plays a major role in long-term survival. Ischemic
mitral valve disease is notoriously a bad disease. If you have
severe mitral valve regurgitation caused by ischemia, your patient
won’t be alive for very many years regardless of whether you do
repair or replacement. Conversely, if you have a myxomatous
mitral valve, they do very well; they do very well with mitral valve
replacement or repair. Did you look at the pathologic process and
the effect it had on survival? Was it different in repair or replace-
ment?
Dr Gillinov. Yes, all patients benefited from repair versus
replacement. The incremental benefit of repair was greatest in
those with rheumatic disease, but it was still present in those with
degenerative disease. Only 1% of the patients in this study had
ischemic disease, so we did not have an adequate number of
patients to comment on patients who have ischemic mitral valve
disease and concomitant aortic valve disease.
Dr David. Yet one of your graphs showed that survival with
mitral valve replacement with a mechanical valve is almost iden-
tical to repair of all causes, telling me perhaps isn’t the mortality
rate largely related to a failed bioprosthesis or the reoperation it
required?
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Dr Gillinov. The slide that had the mechanical valves on it was
freedom from reoperation. The choice of prosthesis when the
mitral valve was replaced did not influence survival rates, but it did
influence durability.
Dr Eugene A. Grossi (New York, NY). I have a question about
freedom from reoperation in the rheumatic group. Was there a
difference in freedom from reoperation between those patients
who had mitral stenosis and primarily had a commissurotomy
versus mitral valve reconstruction for those who had rheumatic
insufficiency?
Dr Gillinov. We did not find any risk factors for reoperation in
the patients with rheumatic mitral valve disease.
Gillinov et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 6 1387
A
CD
